Research Ireland Frontiers for the Future projects to make significant impact by boosting our knowledge and delivering innovations in a wide variety of disciplines and settings.
New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease. The drug has been licensed for use in the UK but rejected by th ...
A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
Donanemab, manufactured by pharmaceutical giant Eli Lilly, is a targeted antibody drug which slows down the early stages of Alzheimer's. It was approved by the medicines regulator on Wednesday, but ...
Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in ...